Prospects for an SV40 vaccine
- 28 February 2001
- journal article
- review article
- Published by Elsevier in Seminars in Cancer Biology
- Vol. 11 (1) , 81-85
- https://doi.org/10.1006/scbi.2000.0349
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Intrapleural administration of interleukin-2 for the treatment of patients with malignant pleural mesotheliomaCancer, 1998
- Preoperative Tumor Volume Is Associated With Outcome In Malignant Pleural MesotheliomaThe Journal of Thoracic and Cardiovascular Surgery, 1998
- Characterization ofin VivoPrimary and Secondary CD8+T Cell Responses Induced by Recombinant Influenza and Vaccinia VirusesCellular Immunology, 1996
- The importance of surgical staging in the treatment of malignant pleural mesotheliomaThe Journal of Thoracic and Cardiovascular Surgery, 1996
- SV40 large tumor antigen associated synthetic peptides define native antigenic determinants and induce protective tumor immunity in miceMolecular Immunology, 1994
- Vaccination with two different vaccinia recombinant viruses: long-term inhibition of secondary vaccinationVaccine, 1993
- Overcoming inhibition of antibody responses to a malaria recombinant vaccinia virus caused by prior exposure to wild type virusVaccine, 1991
- SV40-transformed simian cells support the replication of early SV40 mutantsCell, 1981
- Occurrence of simian virus 40 (SV40)‐reacting antibodies in sera of some patients with prostatic cancerJournal of Surgical Oncology, 1972
- SV40 Neutralizing Antibodies in Sera of US Residents without History of Polio ImmunizationNature, 1971